Global Diabetes Drugs Market 2017-2027

LONDON, August 11, 2017 /PRNewswire/ --

Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others

The global diabetes drugs market was valued at $49.26bn in 2016 and is projected to grow at a CAGR of 6.1% in the first half of the forecast period.to reach global revenue of $66.29bn in 2021. The largest drug class in the market in 2016 was human insulin and analogues. This drug class held 55% share of the global diabetes drugs market in 2016.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you:  

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand-new 262 page report you will receive 75 tables and 141 figures - all unavailable elsewhere.

The 262-page report provides clear detailed insight into the global diabetes drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope: 

• Global Diabetes Drugs Market forecasts from 2017-2027

• Provides qualitative analysis and forecast of the human insulins and analogues submarket for the period 2017-2027:
• Lantus (insulin aspart)
• NovoLog (insulin aspart)
• Humalog (insulin lispro)
• Levemir (insulin detemir)
• Human Insulins by Novo Nordisk
• NovoMix (insulin aspart)
• Humulin (insulin isophane)

• Provides qualitative analysis and forecast of the dipeptidyl peptidase-4 inhibitors (DPP-4) submarket for the period 2017-2027:
• Januvia (sitagliptin)
• Janumet (sitagliptin and metformin)
• Galvus (vidagliptin)
• Onglyza (saxagluiptin)
• Nesina (alogliptin)
• Tradjenta (linagliptin)

• Provides qualitative analysis and forecast of the sulfonylurea submarket for the period 2017-2027:
• Diamicron (gliclazide)
• Amaryl (glimepiride)
• Glucotrol (glipizide)

• Provides qualitative analysis and forecast of the glucagon-like peptide-1 (GLP-1) receptor agonists submarket for the period 2017-2027:
• Victoza (liraglutide)
• Byetta (exenatide)
• Bydureon (exenatide)

• Provides qualitative analysis and forecast of the alpha-glucosidase class submarket for the period 2017-2027:
• Glucobay (acarbose)
• Basen (voglibose)
• Glyset (miglitol)

• Provides qualitative analysis and forecast of the meglitinides submarket for the period 2017-2027:

• Prandin (repaglinide)
• Sarlix (nateglinide)
• Glufast (acarbose).

• Provides qualitative analysis and forecast of the sodium-glucose co-transporter 2 (SGLT2) inhibitors submarket for the period 2017-2027:
• Invokana (canagliflozin)
• Forxiga (dapagliflozin)
• Jardiance (empaglifozin)

• Provides qualitative analysis and forecast of the biguanides submarket for the period 2017-2027:
• Glucophage (metformin)
• Glumetza (metformin)
• Fortamet (metformin)

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• United States
• Japan
• EU5 (Germany, France, UK, Italy, Spain)
• China
• India
• Russia
• Brazil

• This report discusses the SWOT and STEP Analysis of the global diabetes drugs market

• This report also discusses the diabetes R&D pipeline, recent approvals and summarizes anti-diabetes drug developments by Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca and others

Visiongain's study is intended for anyone requiring commercial analyses for the global diabetes drugs market. You find data, trends and predictions.

Buy our report today Global Diabetes Drugs Market 2017-2027: Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others.

To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100

Or click on https://www.visiongain.com/Report/1950/Global-Diabetes-Drugs-Market-2017-2027

Companies Mentioned in the Report: 

Actavis

Alphapharm

Amylin Pharmaceuticals (acquired by Bristol Myers Squibb)

Andromeda Biotech

Arisaph

Astellas Pharma

AstraZeneca

Bayer

Biocon

Blue Cross

Bristol-Myers Squibb

Biogen Idec

Boehringer Ingelheim

Boston Therapeutics

Chugai Pharmaceutical

Diabetes UK

DiaMedica

Diamyd Medical

Eisai

Eli Lilly

Express Scripts

Franco-Indian Pharmaceuticals

Furiex Pharmaceuticals

Genentech

Generex Biotechnology Corporation

GlaxoSmithKline (GSK)

Glenmark Pharmaceuticals

Google

Human Genome Sciences

Intarcia

Janssen (subsidiary of J&J)

Johnson & Johnson (J&J)

Lupin

Kissei Pharmaceuticals

Kotobuki Pharma

Kowa

MannKind Corporation

Mascot Health Series

Merck & Co.

Merck Serono

MSD KK (Asian subsidiary of Merck & Co.)

Mylan

Novartis

Novo Nordisk

Ono Pharmaceuticals

Oramed Pharmaceuticals

Patheon

Pfizer

Ranbaxy Laboratories

Roche

Salix Pharmaceuticals

Sandoz

Sanofi

Santarus (bought by Salix Pharmaceuticals)

Servier

Shantha Biotechnics (acquired by Sanofi)

Shionogi Pharmaceuticals

Shreya Life Sciences

Sun Pharma

Takeda

Taisho Pharmaceutical

Teva Pharmaceutical Industries

Theracos

Transdermal Specialities

Yabao Pharmaceutical

Zydus Cadila

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd